Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcellaâs AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcellaâs AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering. Source
No articles found.
Adamas Pharmaceuticals, Inc. is using its deep understanding of time-dependent bio...
Adamas Pharmaceuticals, Inc. is using its deep ...
Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is...
Merrimack is a biopharmaceutical company based ...
Natural Health Trends Corporation (NASDAQ: NHTC) is an international direct-sellin...
Natural Health Trends Corporation (NASDAQ: NHTC...
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to im...
Five Prime Therapeutics, Inc. discovers and dev...
Join the National Investor Network and get the latest information with your interests in mind.